The poor aqueous solubility acts as a core challenge in oral dosage form development for BCS class II drugs. Phenytoin is taking as a model drug; the present study adopted an innovative solid phospholipid nanoparticle (SPLN) line of attack, and it is parallelly equated with the industrialized methods (freezedrying) which are used for the boosting of solubility and dissolution of Phenytoin. Phenytoin was articulated along with phospholipid and mannitol at a diverse ratio of phenytoin, PL, mannitol, in which 1:12:18 was the correct ratio for ideal preparation. Freeze-drying helps to prepare SPLNs in orbicular shape, which is amorphous in nature with ≤ 1µm diameter on average. While the amorphous matrix-like structure of solid phospholipid dispersion with larger particle size is obtained by freeze-drying technique. Formulating the formulation from this method improved the dissolution rate in a remarkable way. Tris buffer with pH 7.4acts as an apparent solubility dissolved concentration of phenytoin. The poor aqueous solubility acts as a core challenge in oral dosage form development for BCS class II drugs. The decrease in the particle size or cumulating the drug surface area is the widely used practices to proliferate the solubility. The target of the present work was improvisation in solubility, dissolution of a poorly water-soluble drug, and its release by using solid phospholipid nanoparticles. Phenytoin is taking as a model drug. The solid phospholipid nanoparticles were primed by freeze-drying technique along with phospholipid and mannitol in diverse drug to excipients ratios (1:1, 1:2w: w). These preparations were assessed for compatibility study using FTIR, solubility enhancement study by XRD, entrapment ef iciency, surface morphology by SEM, and in-vitro release study. As per the results, there is no in luence of the excipients on the drug used. The solubility was increased by folds compared to in house prepared formulation.
INTRODUCTION
The biggest challenges of API are its poor aqueous solubility and its dissolution rate (Sharma et al., 2015) in pharmaceutical development, and in past twin decades, this is the most common issue in new drug candidates due to the use of large data and combinatorial screening tools at the phase of drug discovery and selection. As per the pharmaceutical classi ication system (Buckley et al., 2013) . The maximum dose power is not soluble in the aqueous vehicle over the PH ranges at 37°C results in a drug compound is poorly soluble and most prob-ably such compounds can be seen in class II drug, which has poor water-solubility and high permeability dependent to the PH of the gastrointestinal luid and may lead to dissolution-limited adsorption (Liu et al., 2010) . Regardless of the high permeability of drugs, less oral bio availability due to slow and limited release of drugs in gastrointestinal luid. Therefore, one of the critical challenges for pharmaceutical industries is to apply drug solubility development in order to convert such problematic compounds into orally bio available and therapeutically effective drugs. To overwhelm the below-par aqueous solubility of drug components have been examined in drug research and development (Balakrishnan et al., 2009 ) through numerous tactics, and one of them is salt formulation. The pro-drug formation, particle size reduction, Complexation, micro-emulsion, Nano-emulsion, Nanosuspension, solid-liquid Nano-particle Brinkmann-Trettenes and Bauer-Brandl, 2014) , and solid dispersion that is considered as one of the most successful approaches to expand the dissolution pro ile of below parsoluble drug Betageri (2008) . "Solid dispersion (Boral et al., 1995) can be de ined as a dispersion of one or more API in an inert carrier or matrix at the solid-state prepared by solvent, melting or solvent melting method". The API in the solid dispersion is dispersed as separate entities (amorphous particle (Babu and Nangia, 2011) , molecule, or crystalline particle), whereas the carrier can be in crystalline or amorphous state (Miller et al., 2012) . A number of studies regarding the solid dispersion (Chiou and Riegelman, 1971 ) have been published and have shown numerous advantageous properties of solid dispersion in enhancing the solubility and dissolution rate of poorly water-soluble drug (Gupta et al., 2007) . The advantages including reduction in particle size, possibly to the molecular level, enhancing wettability and porosity, as well as the change in the nature of the drug (crystalline state, preferably into the amorphous state) (Frank et al., 2012) . In spite of such active research interests, many marketed products produced through solid dispersion techniques (Morgen et al., 2012) is disappointingly low. This can be due to various reasons, mainly during the scale-up process and physicochemical instability during the manufacturing process or during the storage, which may lead to crystallization, phase separation, etc. Very few commercial products have entered the market during the past ive decades. Therefore, very deep knowledge that has been acquired on different features of solid dispersions like carrier properties, preparation models (Butler, 1999) , characteri-zation of physicochemical methods, pharmaceutical mechanisms of matrix formation, and drug release, which are important to safeguard the preparation of an effective and bene icial solid dispersion for marketing. The objective and aim of the current review are to provide the knowledge from recent approaches on solid dispersion ield to overthrow some problems and reasons that ceil the marketability of products through solid dispersion. On the basis of previous literature in this ield, the current article newly suggests four classi ications of solid dispersions based on the advancement over generation-to-generation have been investigated so far and inally, the possible future frame of reference and approaches of solid dispersions are also discussed.
MATERIALS AND METHODS

Material
Phenytoin was obtained from Sigma Aldrich, (Bangalore). Phospholipid was purchased from SD ine chemical, (Mumbai). Mannitol was procured from Akhil Healthcare private limited (Mumbai), and Tert-butanol was purchased from Ponmani &Company, (Chennai). All other chemical was analytical reagent grade.
Method
Preparation of Phenytoin (Dinunizio et al., 2012) formulation by Freeze-drying Method
The contents of the various provisions considered in this analysis are shown in the table. A sum of six details was prepared in two ixed matrices (1) freeze-dried physical mixtures (2). For the preparation for the reasons recently evaluated by our meeting. The ratio between phospholipids and mannitol in total was set at 1: 1: 4. Ethanol in water (75:25) by weight and tert-butanol in water (70:30) by weight was the solvent used to dissolve the lyophilization layer separately.
Physical Blend
Physical mixes of crude material were set up by blending phenytoin, phospholipid, Mannitol utilizing a motor and pestle in 2 distinct arrangements an indicated by theTable 1 Tert-butanol was irst deliquescing in H 2 0 proportion of (70:30, w/w), phenytoin, phospholipid, Mannitol was dissolving in the solvent blending to as indicated by the individual organization depicted. Formulation blending under magnetic storm mixing for 30mins. The formulation was by then freezes Tert-butanol in water at -80ºc for 24 hrs. before set pre-cooled freeze dryer -60ºc. lyophilization was performed by the as indicated by the venture a standard drying stage with rack temperature at 25ºc and weight of 0.1 mbar for 24 hrs. pursued by last drying stage with rack temperature at 25ºc and weight 0.01 mbar for 4hrs. the rest of the substance of common deliquesce was controlled by weighing the sample vials when freeze-drying and was seen to the worthy. (≤ 1%) the vials were ixed and put away at room temperature in a desiccator above calcium chloride the investigation.
Structural analysis (Galia et al., 1998)
The essential structure studies of phenytoin and the diverse plans were inished by an X-ray diffractometer with Cu Kα radiation (1=1.5418 A). the power test was predicated inside the long range of 14-17º 2Ø, with a stage measure of 0.02 beneath the consequents condition stream 11mA, Voltage 40 kV looking at speed 10º 2Ø /mines.
Particle Morphology
The morphology of the phenytoin particles and the different formulations were examined using a scanning electron microscopy with the corresponding parameter. Check the currents at 45 pA and the voltage at 22,000 eV. During the test, a thin layer of gold (20 nm) was closed to improve electrical conductivity using a molecules sputter coater of JEOL. from each vessel and pass through that be µm nylon screen pre-soaked with the medium.
Solubility and dissolution studies
Thermodynamic and apparent solubility Studies (Behera et al., 2010)
The solubility of phenytoin in PBS buffer pH 7.4, as well as the reasonable solubilities 13 of phenytoin, physical mix and freeze-drying formulation within the isolated medium (PBS 7.4), were given by the shake lask container method, overabundance (12 Mg amount of drug) of phenytoin physical mix, formulating were scattered a 4.5ml of the person halfway. These shaking testing was shower (Julabo SW 23 bunch and holm, Demark) and programmed shacked the permitted a 100 rpm until assentation was come to upon adjusting (in the 7day appeared by crucial studies) the test was centrifuged an 11,000 rpm of 1 hrs. to isolate the strong undissolved stage. So they supernatant was a channel through a 0.45µm channel was sometime recently investigating by HPLC all examination was performed in triplicates.
Analytical Method
HPLC/UV was utilizing this estimation of the drug in all inspecting. Chromatographic segment was reached be a turnaround organized approval C 1 section (149mm x 4.8mm for example 3µm particle degree, Thermo isher) out itted with approval screen channel (5µm, Thermo isher) based to our supported procedure (Information not appeared up) isocratic elution with lexible organize including 0.1% formic acid: ethanol (18:82) as the stream rate of the 1ml/min were utilizing and they stove temperature was set up 30ºc. UV of phenytoin setting up 256nm.
RESULTS AND DISCUSSION
The standard plot of Phenytoin in o.1 M Tris buffer
Standard curve of the phenytoin drug was developed, and the perfect correlation was observed from the regression value (R 2 = 0.9989) Figure 1 and it shows that the perfect linearity between the concentration and absorbance was observed when the concentration range was from 2µg/ml to 10µg/ml.
Figure 1: Standard curve of phenytoin
Compatibility studies
FT-IR studies
Fourier transform infrared spectroscopy was performed to check the compatibility between the drug phenytoin and excipients. Table 2 The spectra obtained from IR studies are the length from 4000cm-1 to 400cm-1. After the interpretation, it was observed that no functional group loss in between the spectra of drug and excipients, no major shifting of peak occurred. FT-IR spectra of phenytoin, phenytoin formulation, the physical mixture was shown in Figures 2, 3 and 4
Structural analysis
By de ining crystalline phenytoin with phospholipid and mannitol using the method freeze-drying upon all-out dissolution of the mixes, it is foreseen that an amorphous state would be created. X-beam powder diffraction was working to look at the degree of crystallinity of the crystalline and crude phenytoin. The X-beam diffract gram of the rough phenytoin showed incredibly trademark apices at 2ø extended from 20 to 30º, demonstrating the crystalline idea of phenytoin. After freeze-drying with phospholipid and Mannitol at the various drug and excipient proportions, the X-beam diffract gram showed a trademark crest less paradigm. this showed phenytoin was molecularly scattered inside the Phospholipids in these formulations, in this manner making strong amorphous scattering in all cases. X-ray diffract gram of Pure drug (Phenytoin), physical mixture, Freeze-dried Formulation was shown in Figures 5, 6 and 7
Particle Morphology
Scanning electron microscopy was performed to analyses the surface morphology of rough phenytoin, the formulation of lyophilization with phenytoin, phospholipid, the composition of mannitol 1:12:18. From Figures 8, 9 and 10 The crude phenytoin seemed, by all accounts, to be crystalline and needle-molded with a length of around 10 gm. The watched crystallinity of phenytoin is in concurrence with our X-beam diffractogram result, and with the perception of, the lyophilization formulation demonstrated a round morphology with a distance across running from a few miniaturized micrometers up to the Nano run (less than 1 gm). Amorphous SPLNs 26 have been effectively made by the formulation of phenytoin with phospholipids and mannitol utilizing a lyophilization technique. As of late depicted by our gathering. Then again, it appeared to have a structure like an amorphous network with a lot bigger grain size.
Dissolution studies in pH 7.4 (PBS)
In vitro release study was performed at a pH of 7.4. Determination of in vitro dissolution was carried out using Drug, Formulation, and phosphate buffer (pH 7.4), and the drug release of all three was observed in 60 min. The % cumulative drug release data of all samples were shown in Table 3 and Figure 11 . The results indicated that the % cumulative drug release of FS-2 formulation was found to be 90% after 60 minutes.
Solubility Studies
The apparent solubility studies have been performed for Pure drug, FS-1, and FS-2. They all are having a different-different concentration of solubility. Pure drug (phenytoin) is having a concentration of 1µg/ml, FS-1 is having a concentration of phenytoin is 30µg/ml, and FS-2 is having a concentration of phenytoin is 50µg/ml. The apparent solubility data of phenytoin is shown in Table 4 andFigure 12 FS-2 50 solubility of the drug for their oral dosage form. In the behave of Scanning electron microscopy, x-ray diffraction, dissolution studies, and compatibility studies and lyophilization to estimated their physiochemical property of phospholipid drug, which becomes a promising approach for the bioavailability.
